Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IC351 (tadalafil, Cialis): update on clinical experience.

H Porst1

  • 1Urological practice, Hamburg, Germany. Porst20354@aol.com

International Journal of Impotence Research
|February 19, 2002
PubMed
Summary

Tadalafil (Cialis) is a selective PDE-5 inhibitor showing high efficacy for erectile dysfunction (ED) treatment. Its long half-life allows for spontaneity, with mild side effects like headache and dyspepsia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of prolonged scrotal drainage after penile prosthesis implantation: a multicenter prospective nonrandomized pilot study.

International journal of impotence research·2023
Same author

Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction.

International journal of impotence research·2016
Same author

Results from an online survey investigating ED patients' insights and treatment expectations.

International journal of impotence research·2015
Same author

Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.

International journal of clinical practice·2014
Same author

Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population.

Andrologia·2010
Same author

[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Der Urologe. Ausg. A·2009

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Erectile dysfunction (ED) is a common condition affecting men's sexual health.
  • Phosphodiesterase type 5 (PDE-5) inhibitors are a primary treatment for ED.

Purpose of the Study:

  • To evaluate the efficacy and safety of IC351 (tadalafil) in patients with ED.
  • To assess tadalafil's effectiveness in different dosing regimens and patient populations.

Main Methods:

  • Clinical trials involving daily dosing and as-needed dosing of tadalafil.
  • Placebo-controlled trials in patients with ED, including diabetic patients.

Main Results:

  • High efficacy rates for successful intercourse (up to 93%) and improved erections (up to 88%) were observed.
  • Tadalafil demonstrated significant improvement compared to placebo in diabetic patients (56-64% vs 25%).
  • Adverse effects were mostly mild to moderate, with headache and dyspepsia being most common.

Conclusions:

  • Tadalafil is an effective and well-tolerated treatment for mild to moderate ED.
  • The drug's long half-life enhances spontaneity in sexual activity.
  • Tadalafil offers a favorable safety profile with no serious cardiovascular events or visual disturbances reported.

Related Experiment Videos